|
|
|
|
Search: 
Latin American Herald Tribune
Venezuela Overview
Venezuelan Embassies & Consulates Around The World
Sites/Blogs about Venezuela
Venezuelan Newspapers
Facts about Venezuela
Venezuela Tourism
Embassies in Caracas

Colombia Overview
Colombian Embassies & Consulates Around the World
Government Links
Embassies in Bogota
Media
Sites/Blogs about Colombia
Educational Institutions

Stocks

Commodities
Crude Oil
US Gasoline Prices
Natural Gas
Gold
Silver
Copper

Euro
UK Pound
Australia Dollar
Canada Dollar
Brazil Real
Mexico Peso
India Rupee

Antigua & Barbuda
Aruba
Barbados
Cayman Islands
Cuba
Curacao
Dominica

Grenada
Haiti
Jamaica
Saint Kitts and Nevis
Saint Lucia
Saint Vincent and the Grenadines

Belize
Costa Rica
El Salvador
Honduras
Nicaragua
Panama

Bahamas
Bermuda
Mexico

Argentina
Brazil
Chile
Guyana
Paraguay
Peru
Uruguay

What's New at LAHT?
Follow Us On Facebook
Follow Us On Twitter
Most Viewed on the Web
Popular on Twitter
Receive Our Daily Headlines


  HOME | Science, Nature & Technology

China's CanSino Files for Authorization to Market Covid Vaccine

BEIJING -- Chinese vaccine maker CanSino Biologics announced Wednesday that the National Medical Products Administration (NMPA) is processing its request for marketing authorization for its Covid-19 vaccine in the Asian country.

In a statement sent to the Hong Kong Stock Exchange, CanSino said after completing the third phase of clinical trials, its vaccine has 65.28 percent efficacy in preventing all Covid-19 symptoms 28 days after vaccination and 95.47 percent efficacy in preventing serious cases after 14 days.

According to the company, the vaccine meets all the technical standards established by the World Health Organization and by Chinese regulators and approved for use in Mexico that has already received more than two million doses.

The clinical trials were conducted in Mexico, Pakistan, Russia, Chile, and Argentina with the vaccination of more than 40,000 volunteers, according to CanSino.

The serum has been jointly developed by CanSino and the Beijing Institute of Biotechnology under the Academy of Military Medical Science.

On Dec. 31, the Chinese authorities approved for general public distribution a homegrown coronavirus vaccine developed by a unit of the China National Biotec Group (CNBG), an affiliate of state-owned pharma giant Sinopharm, and its subsidiary, Beijing Institute of Biological Products.

In early February, another Covid-19 vaccine, developed by local company Sinovac, also received "conditional marketing approval" from the NMPA.

Sinovac said at the time that the vaccine has already been given "to tens of thousands of people in China as part of an emergency use program launched in July that targeted specific groups at high risk of infection."

Sinopharm alone has already distributed 43 million doses of its vaccine, of which 34 million have been administered in the Asian country, whose vaccination campaign is confined, for the moment, to groups considered to be at high risk of contracting Covid-19, according to state broadcaster CCTV.
 

Enter your email address to subscribe to free headlines (and great cartoons so every email has a happy ending!) from the Latin American Herald Tribune:

 

Copyright Latin American Herald Tribune - 2005-2021 © All rights reserved